Oncolytics Biotech (ONCY) News Today $0.42 +0.02 (+4.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.43 +0.01 (+1.82%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Q2 EPS Estimates for Oncolytics Biotech Cut by HC WainwrightMay 25 at 1:19 AM | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Oncolytics Biotech (NASDAQ:ONCY)May 24 at 3:09 AM | americanbankingnews.comOncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation CapabilitiesMay 23 at 7:00 AM | prnewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by BrokeragesMay 21, 2025 | americanbankingnews.comOncolytics Biotech's (ONCY) Hold Rating Reaffirmed at Jones TradingMay 19, 2025 | americanbankingnews.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Immunome (IMNM), Oncolytics Biotech (ONCY) and Hookipa Pharma (HOOK)May 18, 2025 | theglobeandmail.comJones Trading Downgrades Oncolytics Biotech (ONCY)May 17, 2025 | msn.comOncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical MomentumMay 17, 2025 | finanznachrichten.deOncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comOncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comOncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical MomentumMay 14, 2025 | prnewswire.comOncolytics Biotech to Discuss Q1 2025 Financial Results on May 14May 8, 2025 | tipranks.comOncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational HighlightsMay 6, 2025 | prnewswire.comOncolytics Biotech, Inc. Common Shares (ONCY) Latest After Hours TradesMay 4, 2025 | nasdaq.comOncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of ActionApril 24, 2025 | prnewswire.comAs Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer TreatmentsApril 14, 2025 | baystreet.caOncolytics Biotech Secures $20 Million Funding for Pelareorep DevelopmentApril 10, 2025 | tipranks.comOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni CapitalApril 10, 2025 | prnewswire.comOncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic CancersApril 10, 2025 | prnewswire.comWhat is HC Wainwright's Estimate for ONCY FY2027 Earnings?Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - HC Wainwright upped their FY2027 earnings per share (EPS) estimates for Oncolytics Biotech in a research report issued on Monday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.08) per share for the yeMarch 14, 2025 | marketbeat.comLeede Financial Has Positive Outlook of ONCY FY2025 EarningsOncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Investment analysts at Leede Financial raised their FY2025 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued to investors on Monday, March 10th. Leede Financial analyst D. Loe now forecasts that the company wiMarch 14, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Oncolytics BiotechOncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Investment analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued to investors on Monday, March 10th. HC Wainwright analyst P. Trucchio now forecasts that the companyMarch 13, 2025 | marketbeat.comMaxim Group Issues Pessimistic Forecast for Oncolytics Biotech (NASDAQ:ONCY) Stock PriceMaxim Group lowered their price objective on Oncolytics Biotech from $5.00 to $3.00 and set a "buy" rating for the company in a report on Monday.March 11, 2025 | marketbeat.comOncolytics Biotech's (ONCY) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $5.00 price target on shares of Oncolytics Biotech in a research report on Monday.March 11, 2025 | marketbeat.comRoyal Bank of Canada Cuts Oncolytics Biotech (NASDAQ:ONCY) Price Target to $5.00Royal Bank of Canada lowered their price target on shares of Oncolytics Biotech from $6.00 to $5.00 and set an "outperform" rating for the company in a research report on Monday.March 11, 2025 | marketbeat.comOncolytics price target lowered to $3 from $5 at MaximMarch 10, 2025 | markets.businessinsider.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comOncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings ResultsOncolytics Biotech (NASDAQ:ONCY - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01.March 8, 2025 | marketbeat.comOncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call TranscriptMarch 7, 2025 | seekingalpha.comOncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024March 7, 2025 | prnewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Short Interest Down 14.1% in FebruaryOncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 3,050,000 shares, a decrease of 14.1% from the January 31st total of 3,550,000 shares. Based on an average daily volume of 1,150,000 shares, the short-interest ratio is presently 2.7 days.March 5, 2025 | marketbeat.comOncolytics Biotech (ONCY) to Release Quarterly Earnings on FridayOncolytics Biotech (NASDAQ:ONCY) will be releasing earnings before the market opens on Friday, March 7, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669693)February 28, 2025 | marketbeat.comWorld Cancer Day Sparks Big Questions About Pollution, Genetics, and InnovationFebruary 27, 2025 | baystreet.caUSA News Group: Oncology Breakthroughs: How Cancer Research Is Advancing in 2025February 27, 2025 | finanznachrichten.deOncolytics Biotech to Discuss 2024 Financial Results and Operational HighlightsFebruary 25, 2025 | tipranks.comOncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational HighlightsFebruary 25, 2025 | prnewswire.comOncolytics Biotech advances pancreatic, anal cancer trialsFebruary 20, 2025 | markets.businessinsider.comUSA News Group: Investors Eye Biotech Sector as Cancer Therapy Market SurgesFebruary 19, 2025 | finanznachrichten.deOncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025February 19, 2025 | prnewswire.comOncolytics provides progress update for pelareorep in pancreatic and anal cancerFebruary 18, 2025 | markets.businessinsider.comOptimism in War on Cancer on the Rise, as Biotech Companies Roll Out More WinsFebruary 18, 2025 | baystreet.caOncolytics making progress in 2025 with regulatory, clinical advancementsFebruary 18, 2025 | markets.businessinsider.comOncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast CancerFebruary 18, 2025 | prnewswire.comShort Interest in Oncolytics Biotech Inc. (NASDAQ:ONCY) Rises By 35.0%Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 3,550,000 shares, a growth of 35.0% from the January 15th total of 2,630,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is currently 3.0 days.February 17, 2025 | marketbeat.comOncolytics receives noncompliance notification from NasdaqFebruary 14, 2025 | markets.businessinsider.comOncolytics Biotech faces Nasdaq delisting over share priceFebruary 14, 2025 | msn.comOncolytics Biotech Receives Nasdaq Notification for Bid Price DeficiencyFebruary 14, 2025 | tipranks.comOncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyFebruary 14, 2025 | prnewswire.comOncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of AbsenceFebruary 7, 2025 | prnewswire.comWhat is HC Wainwright's Estimate for ONCY FY2024 Earnings?Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Analysts at HC Wainwright upped their FY2024 EPS estimates for Oncolytics Biotech in a research report issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.28) per share for the year, uFebruary 5, 2025 | marketbeat.com Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCY Media Mentions By Week ONCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONCY News Sentiment▼-0.360.77▲Average Medical News Sentiment ONCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONCY Articles This Week▼92▲ONCY Articles Average Week Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Silence Therapeutics News Today Korro Bio News Today Aclaris Therapeutics News Today Fate Therapeutics News Today Eupraxia Pharmaceuticals News Today Inhibikase Therapeutics News Today Greenwich LifeSciences News Today Protalix BioTherapeutics News Today Protara Therapeutics News Today FitLife Brands News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONCY) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
